Pharsight

Nubeqa patents expiration

NUBEQA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(8 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

Nubeqa is owned by Bayer Healthcare.

Nubeqa contains Darolutamide.

Nubeqa has a total of 8 drug patents out of which 0 drug patents have expired.

Nubeqa was authorised for market use on 30 July, 2019.

Nubeqa is available in tablet;oral dosage forms.

Nubeqa can be used as treatment of patients with non-metastatic castration resistant prostate cancer.

Drug patent challenges can be filed against Nubeqa from 31 July, 2023.

The generics of Nubeqa are possible to be released after 27 February, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

Family Patents